LIVECAST Markets Briefs Calendar Search

Research

AI Market Assistant Instrument directory Macro Politics Prediction Markets News Archive

LIVECAST Markets

☀◐Theme

Menu

Home LIVECAST Markets Briefs Calendar Search AI Market Assistant Instrument directory Macro Politics Prediction Markets News Archive Account

Live News REGULATION FLASH L impact Sep 28, 2026, 10:18 AM UTC

Stepan Co - Enters Credit Agreement On Sept 25, 2026 - SEC Filing

Stepan Co NYSE:SCL

SquawkNews Newsroom

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

SCL

Related stories

Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate ARV-6723 is an investigational, oral PROTAC designed to degrade HPK1, a negative regulator of immune activation, in advanced solid tumors —NEW HAVEN, Conn., Sept. 28, 2026 (GLOBE N L impact | REGULATION | Sep 28, 2026, 11:08 AM UTC Vestis appoints Russell Tiejema as EVP and Chief Financial Officer Vestis appointed Russell Tiejema as Executive Vice President and Chief Financial Officer, effective September 28, 2026.Original SEC Filing: Vestis Corp [ VSTS ] - 8-K - Sep. 28, 20 L impact | REGULATION | Sep 28, 2026, 11:08 AM UTC Moleculin Announces Peer-Reviewed Analysis Finds No Cardiotoxicity with Annamycin at High Cumulative Doses Moleculin announced a peer-reviewed pooled analysis showing no clinical or subclinical cardiotoxicity with Annamycin across 90 patients.Key Highlights:Original SEC Filing: Moleculi L impact | REGULATION | Sep 28, 2026, 11:08 AM UTC Flutter suspends Brazil operations; forecasts ~$70m revenue, ~$20m adjusted EBITDA hit for 2026 Flutter ceased operations in Brazil after a provisional executive order and expects a c.$70m revenue and c.$20m adjusted EBITDA reduction for 2026.Key Highlights:Original SEC Filin L impact | REGULATION | Sep 28, 2026, 11:08 AM UTC Weekly Recap: Phase2 ARCT-2601 addition and FDA pediatric ammonia endpoint Arcturus Therapeutics Holdings, Inc. (NASDAQ:ARCT) will add ARCT-2601 to its Phase 2 ARCT-810 trial after an FDA meeting, planning year—end dosing in OTCD patients to assess safety L impact | REGULATION | Sep 28, 2026, 11:08 AM UTC Weekly Recap: Tegoprubart 24—month kidney benefit and FDA fast—track, +13% Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) saw shares surge after the FDA granted fast-track status to tegoprubart following Phase 2 results showing significantly better kidney fun L impact | REGULATION | Sep 28, 2026, 11:07 AM UTC

SQUAWK/NEWS

Live financial news for traders. Read the headline on screen or hear it through LiveCast while you stay on the trade.

LiveCast passes from $15 · Institutional API access.

Start LiveCast

Product

Open LiveCast
Plans & Pricing
Institutional API
How LiveCast Works
Live Markets
Session Briefs
RSS Feed
Calendar
Search
Instrument directory

Research

Macro
Politics
Prediction Markets
AI Market Assistant
News Archive

For Traders

Market Movers
US Stocks
Why News Moves Markets
News for Traders
How to Trade the News
What Is an Audio Squawk?
Policy Calendar

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact us

Legal

Privacy Policy
Terms of Use

© 2026 SquawkNews SquawkNews publishes market information and context. It does not provide investment advice or trade recommendations.